ZhuZhou QianJin Pharmaceutical Co Ltd (SHG:600479) — Market Cap & Net Worth
Market Cap & Net Worth: ZhuZhou QianJin Pharmaceutical Co Ltd (600479)
ZhuZhou QianJin Pharmaceutical Co Ltd (SHG:600479) has a market capitalization of $793.00 Million (CN¥5.42 Billion) as of May 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #10205 globally and #2929 in its home market, demonstrating a 5.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ZhuZhou QianJin Pharmaceutical Co Ltd's stock price CN¥11.01 by its total outstanding shares 492210016 (492.21 Million). Analyse 600479 operating cash flow to see how efficiently the company converts income to cash.
ZhuZhou QianJin Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
ZhuZhou QianJin Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $897.87 Million to $793.00 Million (1.11% CAGR).
ZhuZhou QianJin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ZhuZhou QianJin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
ZhuZhou QianJin Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.33x
ZhuZhou QianJin Pharmaceutical Co Ltd's market cap is 3.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $897.87 Million | $2.45 Billion | $92.96 Million | 0.37x | 9.66x |
| 2016 | $681.28 Million | $2.86 Billion | $149.43 Million | 0.24x | 4.56x |
| 2017 | $614.11 Million | $3.18 Billion | $207.76 Million | 0.19x | 2.96x |
| 2018 | $417.95 Million | $3.33 Billion | $255.36 Million | 0.13x | 1.64x |
| 2019 | $492.51 Million | $3.53 Billion | $294.31 Million | 0.14x | 1.67x |
| 2020 | $511.43 Million | $3.63 Billion | $297.07 Million | 0.14x | 1.72x |
| 2021 | $827.01 Million | $3.66 Billion | $302.06 Million | 0.23x | 2.74x |
| 2022 | $670.27 Million | $4.03 Billion | $302.51 Million | 0.17x | 2.22x |
| 2023 | $775.72 Million | $3.80 Billion | $320.41 Million | 0.20x | 2.42x |
| 2024 | $769.24 Million | $3.63 Billion | $230.76 Million | 0.21x | 3.33x |
Competitor Companies of 600479 by Market Capitalization
Companies near ZhuZhou QianJin Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to ZhuZhou QianJin Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
ZhuZhou QianJin Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, ZhuZhou QianJin Pharmaceutical Co Ltd's market cap moved from $897.87 Million to $ 793.00 Million, with a yearly change of 1.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥793.00 Million | +8.37% |
| 2025 | CN¥731.78 Million | -4.87% |
| 2024 | CN¥769.24 Million | -0.84% |
| 2023 | CN¥775.72 Million | +15.73% |
| 2022 | CN¥670.27 Million | -18.95% |
| 2021 | CN¥827.01 Million | +61.71% |
| 2020 | CN¥511.43 Million | +3.84% |
| 2019 | CN¥492.51 Million | +17.84% |
| 2018 | CN¥417.95 Million | -31.94% |
| 2017 | CN¥614.11 Million | -9.86% |
| 2016 | CN¥681.28 Million | -24.12% |
| 2015 | CN¥897.87 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of ZhuZhou QianJin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $793.00 Million USD |
| MoneyControl | $793.00 Million USD |
| MarketWatch | $793.00 Million USD |
| marketcap.company | $793.00 Million USD |
| Reuters | $793.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ZhuZhou QianJin Pharmaceutical Co Ltd
ZhuZhou QianJin Pharmaceutical Co.,Ltd researches, develops, produces, and sells traditional Chinese medicines, chemicals and API, and TCM derivatives in China. The company offers TCM products, chemical medicine, derivative products, and hygienic products, including gynaecological and baby nursing, and maternity pad/ maternity package. ZhuZhou QianJin Pharmaceutical Co.,Ltd was founded in 1966 an… Read more